Management of newly diagnosed glioblastoma multiforme: current state of the art and emerging therapeutic approaches

Medicine and Dentistry

• Glioblastoma 100%
• Targeted Therapy 50%
• Immunotherapy 50%
• Hope 50%
• Temozolomide 50%
• Ganglioglioma 25%
• Clinical Research 25%
• Clinical Trial 25%
• Radiation Therapy 25%
• Symptomatic Treatment 25%
• Five-Year Survival Rate 25%
• Surgical Technique 25%
• Antiangiogenic Therapy 25%
• Lomustine 25%
• Tumor Treating Fields 25%
• Tumor 25%
• Cognitive Decline 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Glioblastoma 100%
• Immunotherapy 50%
• Temozolomide 50%
• Neoplasm 25%
• Clinical Trial 25%
• Clinical Research 25%
• Survival Rate 25%
• Antiangiogenic Therapy 25%
• Lomustine 25%

Neuroscience

• Glioblastoma Multiforme 100%
• Immunotherapy 66%
• Temozolomide 66%
• Radiation Therapy 33%
• Tumor Treating Fields 33%
• Lomustine 33%